Robert W. Baird Boosts Illumina (NASDAQ:ILMN) Price Target to $139.00

Illumina (NASDAQ:ILMN - Get Free Report) had its price target hoisted by analysts at Robert W. Baird from $124.00 to $139.00 in a report released on Wednesday, Benzinga reports. The brokerage presently has a "neutral" rating on the life sciences company's stock. Robert W. Baird's target price suggests a potential downside of 8.45% from the company's current price.

ILMN has been the subject of a number of other research reports. Royal Bank of Canada lifted their target price on shares of Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research note on Tuesday. Scotiabank reduced their price objective on shares of Illumina from $176.00 to $164.00 and set a "sector outperform" rating for the company in a research note on Thursday, August 15th. Hsbc Global Res upgraded Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a research note on Thursday, October 17th. UBS Group lifted their price objective on Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a report on Tuesday. Finally, Canaccord Genuity Group upped their price objective on Illumina from $130.00 to $145.00 and gave the company a "hold" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $162.18.

Illumina Price Performance

ILMN traded down $3.13 on Wednesday, reaching $151.83. The company had a trading volume of 2,815,785 shares, compared to its average volume of 1,731,745. Illumina has a one year low of $89.00 and a one year high of $156.66. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The company has a fifty day moving average of $137.27 and a 200-day moving average of $123.12.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter last year, the firm posted $0.33 EPS. The business's revenue for the quarter was down 3.5% on a year-over-year basis. As a group, research analysts expect that Illumina will post 3.62 EPS for the current year.

Institutional Trading of Illumina

Several large investors have recently modified their holdings of ILMN. Primecap Management Co. CA grew its stake in shares of Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company's stock valued at $253,514,000 after buying an additional 1,997,010 shares during the period. Millennium Management LLC raised its position in Illumina by 305.0% in the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company's stock worth $155,067,000 after acquiring an additional 1,118,747 shares during the period. Capital World Investors raised its stake in shares of Illumina by 41.1% in the first quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company's stock valued at $378,111,000 after buying an additional 801,814 shares during the period. Marshall Wace LLP bought a new stake in Illumina in the 2nd quarter valued at about $77,628,000. Finally, Swedbank AB bought a new stake in shares of Illumina in the first quarter valued at approximately $99,682,000. Institutional investors and hedge funds own 89.42% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.